推薦產品
product name
SB 203580, SB 203580, CAS 152121-47-6, is a highly specific, potent, cell-permeable, selective, reversible, and ATP-competitive inhibitor of p38 MAP kinase (IC₅₀ = 34 nM in vitro, 600 nM in cells).
品質等級
化驗
≥98% (HPLC)
形狀
film (Thin)
製造商／商標名
Calbiochem®
儲存條件
OK to freeze
protect from light
溶解度
DMSO: 30 mg/mL
運輸包裝
ambient
儲存溫度
−20°C
InChI
1S/C21H16FN3OS/c1-27(26)18-8-4-16(5-9-18)21-24-19(14-2-6-17(22)7-3-14)20(25-21)15-10-12-23-13-11-15/h2-13H,1H3,(H,24,25)
InChI 密鑰
CDMGBJANTYXAIV-UHFFFAOYSA-N
一般說明
降低表阿霉素诱导的细胞损伤和caspase-3/7活性。p38 MAP激酶的一种高度特异性、有效性、细胞渗透性、选择性、可逆性和ATP竞争性抑制剂（体外IC50=34 nM，细胞内为600 nM）。在100 µM时不会显著抑制JNK和p42 MAP激酶。抑制LPS刺激的人单核细胞和人单核细胞系THP-1产生IL-1和TNFα（IC50=50-100 nM）。抑制骨形态发生蛋白-2诱导的PC12细胞突起生长。还可抑制由胶原蛋白（IC50 = 0.2-1.0 µM）或血栓素类似物U-46619（目录号538944）引起的血小板聚集。也可提供SB 203580（目录号559398）在无水DMSO中的1 mg/ml溶液。
降低表阿霉素诱导的细胞损伤和caspase-3/7活性。p38激酶的一种高度特异性、有效性、细胞渗透性、选择性、可逆性和ATP竞争性抑制剂（体外IC50=34 nM，细胞内为600 nM）。也称为再激活激酶（RK）和CSBP（细胞因子合成抗炎药物结合蛋白）。即使在100 µM时也不会显著抑制JNK或p42 MAP激酶。抑制LPS刺激的人单核细胞和人单核细胞系THP-1产生IL-1和TNFα（IC50=50-100 nM）。SB203580也被证明是小鼠和大鼠体内炎症细胞因子产生的有效抑制剂。
生化／生理作用
产物与ATP竞争。
可逆性：是
细胞可渗透性：是
靶标IC50：在体外对p38 MAP激酶为34 nM，在细胞中为600 nM；对LPS刺激的人单核细胞和人单核细胞系TNF-α产生的IL-1和TNF-为50-100 nM；对胶原蛋白引起的血小板聚集为0.2-1.0 µM
警告
毒性：刺激性（B）
其他說明
Yamada.T., et al. 2012.Free Radic.Biol. Med. (In press)
Powell, D.J., et al. 2003.Mol.Cell Biol.23, 7794.
Davies, S.P., et al. 2000.Biochem.J.351, 95.
Iwasaki, S., et al. 1999.J. Biol. Chem.274, 26503.
Gallagher, T.F., et al. 1997.Bioorg.Med. Chem. 5, 49.
LoGrasso, P.V., et al. 1997.Biochem.36, 10422.
Hazzalin, C.A., et al. 1996.Curr.Biol.6, 1028.
Kramer, R.M., et al. 1996.J. Biol. Chem.271, 27723.
Saklatvala, J., et al. 1996.J. Biol. Chem. 271, 6586.
Cuenda, A., et al. 1995.FEBS Lett.364, 229.
Gallagher, T.F., et al. 1995.Bioorg.Med. Chem. Lett.5, 1171.
Lee, J.C., et al. 1994.Nature 372, 739.
Powell, D.J., et al. 2003.Mol.Cell Biol.23, 7794.
Davies, S.P., et al. 2000.Biochem.J.351, 95.
Iwasaki, S., et al. 1999.J. Biol. Chem.274, 26503.
Gallagher, T.F., et al. 1997.Bioorg.Med. Chem. 5, 49.
LoGrasso, P.V., et al. 1997.Biochem.36, 10422.
Hazzalin, C.A., et al. 1996.Curr.Biol.6, 1028.
Kramer, R.M., et al. 1996.J. Biol. Chem.271, 27723.
Saklatvala, J., et al. 1996.J. Biol. Chem. 271, 6586.
Cuenda, A., et al. 1995.FEBS Lett.364, 229.
Gallagher, T.F., et al. 1995.Bioorg.Med. Chem. Lett.5, 1171.
Lee, J.C., et al. 1994.Nature 372, 739.
法律資訊
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
訊號詞
Warning
危險聲明
危險分類
Acute Tox. 4 Oral
儲存類別代碼
13 - Non Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
分析證明 (COA)
輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。
客戶也查看了
Jayoung Kim et al.
Journal of cancer science and clinical therapeutics, 5(4), 434-447 (2021-01-01)
Stress granules (SGs) are cytoplasmic aggregates to reprogram gene expression in response to cellular stimulus. Here, we show that while SGs are being assembled in response to clotrimazole, an antifungal medication heterogeneous nuclear ribonucleoprotein (hnRNP) K, an RNA-binding protein that
Rhiannon B Werder et al.
Science advances, 8(28), eabo6566-eabo6566 (2022-07-21)
Genome-wide association studies (GWAS) have identified dozens of loci associated with chronic obstructive pulmonary disease (COPD) susceptibility; however, the function of associated genes in the cell type(s) affected in disease remains poorly understood, partly due to a lack of cell
Lingfei Li et al.
Cell communication and signaling : CCS, 20(1), 115-115 (2022-07-29)
Diabetic nephropathy (DN) involves various structural and functional changes because of chronic glycemic assault and kidney failure. Proteinuria is an early clinical manifestation of DN, but the associated pathogenesis remains elusive. This study aimed to investigate the role of microtubule
Milica Bozic et al.
Nature communications, 11(1), 1943-1943 (2020-04-25)
Kidney fibrosis is a highly deleterious process and a final manifestation of chronic kidney disease. Alpha-(α)-synuclein (SNCA) is an actin-binding neuronal protein with various functions within the brain; however, its role in other tissues is unknown. Here, we describe the
Beatriz Rendon-Mitchell et al.
Journal of immunology (Baltimore, Md. : 1950), 170(7), 3890-3897 (2003-03-21)
We recently discovered that a ubiquitous protein, high mobility group box 1 protein (HMGB1), is released by activated macrophages, and functions as a late mediator of lethal systemic inflammation. To elucidate mechanisms underlying the regulation of HMGB1 release, we examined
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務